Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden

Table 4 Base case analysis results

	Costs (SEK)					Effects
	Drug	Hospital	AEs	Monitoring	Total costs	LYs	QALYs
Isavuconazole
IA^a	143,966	192,098	6819	1690	344,573	9.07	7.43
Mucormycosis^a	18,489	11,427	331	307	30,554	0.45	0.37
Combined	162,455	203,525	7150	1996	375,127	9.51	7.80
Voriconazole
IA^a	96,872	192,098	8395	2617	299,982	9.07	7.43
Mucormycosis^a	10,877	11,582	438	58	22,954	0.08	0.07
Combined	107,749	203,680	8832	2675	322,936	9.15	7.50
Difference (isavuconazole−voriconazole)					52,191		0.3
						ICER (SEK/ QALY) 174,890

AE adverse event, IA invasive aspergillosis, ICER incremental cost-effectiveness ratio, LY life year, QALY quality-adjusted life year, SEK Swedish krona
^aThe costs and effects for IA and mucormycosis are weighted by their relative proportions, e.g., 94% for IA and 6% for mucormycosis

ISSN: 1471-2334